CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation

Bladder cancer (BC) and melanoma are amenable to immune checkpoint blockade (ICB) therapy, yet most patients with advanced/metastatic disease do not respond. CD122-targeted interleukin (IL)-2 can improve ICB efficacy, but mechanisms are unclear. We tested αPD-L1 and CD122-directed immunotherapy with...

Full description

Saved in:
Bibliographic Details
Main Authors: Ryan M Reyes, Chenghao Zhang, Yilun Deng, Niannian Ji, Neelam Mukherjee, Alvaro S Padron, Curtis A Clark, Robert S Svatek, Tyler J Curiel
Format: article
Language:EN
Published: Taylor & Francis Group 2021
Subjects:
preclinical
immunotherapy
lymphocyte activation
tumor microenvironment
urinary tissue-specific microenvironment
melanoma
bladder cancer
immune checkpoint blockade
il-2
cd122
nk cells
metastasis
Immunologic diseases. Allergy
RC581-607
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Online Access:https://doaj.org/article/6f57b3a6ecf3451ead7b6bb61c301abc
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/6f57b3a6ecf3451ead7b6bb61c301abc

Similar Items